Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyoscine as Adjuvant for Second Trimester Abortion Induction
NCT06207539Phase 1Completed
- Sponsor
- Ain Shams University Maternity Hospital
- Start
- Dec 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hyoscine butylbromide in abortion, sponsored by Ain Shams University Maternity Hospital. Primary endpoint: Time from first dose of misoprostol to abortion. Started Dec 2022; status: completed.
02
Drugs
hyoscine butylbromide
03
Conditions
abortion
Beyond the preview
Go deeper on NCT06207539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207539.